The human heart is divided into four chambers. One of the four chambers, the left ventricle, is the chamber mainly responsible for pumping blood out of the heart into the circulation. Diseases of the heart like congestive heart failure (CHF), can cause the left ventricle to function improperly. Medications called beta-blockers appear to reverse the abnormalities in the left ventricle and...
Date First Received: November 3, 1999
Last Updated: March 3, 2008
Verified by: National Institutes of Health Clinical Center (CC), December 1999
Clinical Trial Phase: Phase 2 | Start Date: January 1994
Overall Status: Completed
Estimated Enrollment: 130
Brief Summary
Official Title: “Assessment of Metabolic Function and Perfusion Using Positron Emission Tomography: An Analysis of Patients With Congestive Cardiomyopathy Before and After Beta-Blockers”
Condition Keyword(s):
Intervention(s):
The human heart is divided into four chambers. One of the four chambers, the left ventricle, is the chamber mainly responsible for pumping blood out of the heart into the circulation.
Diseases of the heart like congestive heart failure (CHF), can cause the left ventricle to function improperly.
Medications called beta-blockers appear to reverse the abnormalities in the left ventricle and frequently improve the function of the left ventricle in patients with different kinds of heart disease. How beta-blockers improve left ventricle function is unknown.
One possible reason for improved function of the left ventricle with beta-blockers is improved blood flow to the heart muscle. When a region of the heart is active, it uses more fuel in the form of oxygen and sugar (glucose). As heart activity increases, blood flow to and from the area of activity increases also. Knowing these facts, researchers can use radioactive sugar (glucose) and positron emission tomography (PET) scans to observe what areas of the heart are receiving more blood flow.
In this study researchers plan to measure glucose use in heart muscle and blood flow to the heart muscle in patients with CHF taking beta-blockers.
Study Type: Interventional
Study Design: Treatment, Safety/Efficacy Study
Detailed Clinical Trial Description
Deterioration in left ventricular function, which is characteristic in patients with congestive heart failure, appears to be a multifactorial process. Beta-blockers appear to reverse the deterioration and frequently improve left ventricular function in patients with both ischemic and non-ischemic cardiomyopathies. The mechanism by which beta-blockers improve ejection fraction is not known. Although it is well established that regional flow, function and metabolism may improve after coronary revascularization whether beta-blocker therapy will have similar salutary results in patients with congestive heart failure is unknown. The aim of this study is to: 1) quantitate regional glucose uptake and regional blood flow before and after chronic beta-blocker administration to patients with congestive heart failure using positron emission tomography, 2) determine if alteration in either regional glucose or lipid uptake or regional blood flow correlate with improvement in wall motion and global left ventricular function, and 3) determine if ischemic and nonischemic myocardium differ in blood flow or metabolism.
Intervention(s) in this Clinical Trial
- Device: PET scan
Criteria for Participation in this Clinical Trial
- Left ventricular ejection fraction by radionuclide angiography of less than or equal to 40%.
- New York Heart Association class II, III or IV symptoms on standard heart failure medications which my include digoxin, diuretics and angiotensin converting enzyme inhibitors for at least one month prior to enrollment.
- Ischemic cardiomyopathy if enzymes document an MI or 70% or greater stenosis in one major vessel.
- Dilated cardiomyopathy-if no coronary disease.
- No pregnant or lactating women.
- No women of child-bearing age not on proven birth control.
- No severe hepatic or renal disease.
- No diabetes mellitus or fasting glucose greater than or equal to 120 mg/dl.
- No primary valvular heart disease.
- No PTCA or CABG within 3 months of enrollment.
- No history of myocardial infarction or unstable angina within past 2 months.
- No resting heart rate less than 60 bpm.
- No A-V block greater than 1 degree block without pacemaker.
- No severe ETOH abuse within 6 months of enrollment.
- No severe bronchospasm.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: N/A
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Related Publications
References
Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994 Nov 1;24(5):1310-20.
Kjekshus JK, Mjos OD. Effect of free fatty acids on myocardial function and metabolism in the ischemic dog heart. J Clin Invest. 1972 Jul;51(7):1767-76. No abstract available.
Additional Information
Information obtained from ClinicalTrials.gov on September 05, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00001402
Study ID Number: 940054
ClinicalTrials.gov Identifier: NCT00001402
Health Authority: United States: Federal Government
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
